Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922

• DOI: 10.18632/oncotarget.10414
• Publication Date: 2016-07-06T13:31:48Z
• Authors: Chun Yan Wang; Su Tang Guo; Jia Yu Wang; Xu Guang Yan; Margaret Farrelly; Yuan Yuan Zhang; Fen Liu; Hamed Yari; Ting La; Fu Xi Lei; Lei Jin; Xu Dong Zhang; Chen Chen Jiang
• Keywords: Proto-Oncogene Proteins B-raf; Chaperonins; Cell Survival; Apoptosis; Cell Cycle Proteins; oncogenic mutations; BRAF; 03 medical and health sciences; colon cancers; Cell Line, Tumor; 616; Humans; HSP90 Heat-Shock Proteins; Extracellular Signal-Regulated MAP Kinases; 0303 health sciences; Isoxazoles; Resorcinols; Xenograft Model Antitumor Assays; 3. Good health; Gene Expression Regulation, Neoplastic; Drug Resistance, Neoplasm; Colonic Neoplasms; Mutation; cancer cells; Proto-Oncogene Proteins c-akt; Research Paper

Oncogenic mutations of BRAF occur in approximately 10% of colon cancers and are associated with their resistance to clinically available therapeutic drugs and poor prognosis of the patients. Here we report that colon cancer cells with mutant BRAF are also resistant to the heat shock protein 90 (HSP90) inhibitor AUY922, and that this is caused by rebound activation of ERK and Akt. Although AUY922 triggered rapid reduction in ERK and Akt activation in both wild-type and mutant BRAF colon cancer cells, activation of ERK and Akt rebounded shortly in the latter leading to resistance of the cells to AUY922-induced apoptosis. Reactivation of ERK was associated with the persistent expression of mutant BRAF, which, despite being a client of HSP90, was only partially degraded by AUY922, whereas reactivation of Akt was related to the activity of the HSP90 co-chaperone, cell division cycle 37 (CDC37), in that knockdown of CDC37 inhibited Akt reactivation in mutant colon cancer cells treated with AUY922. In support, as a HSP90 client protein, Akt was only diminished by AUY922 in wild-type but not mutant BRAF colon cancer cells. Collectively, these results reveal that reactivation of ERK and Akt associated respectively with the activity of mutant BRAF and CDC37 renders mutant BRAF colon cancer cells resistant to AUY922, with implications of co-targeting mutant BRAF and/or CDC37 and HSP90 in the treatment of mutant BRAF colon cancers.